NY med schools: clerkships are scarce because of offshore competition

Medical school students in New York are having trouble finding available clinical clerkships because for-profit, offshore medical schools are paying up to $400 per week for a single slot, according to the Wall Street Journal.

American schools typically don’t offer money for clerkship slots, instead offering hospitals the benefit of being affiliated with their university in exchange for helping train students in their third and fourth years of medical school.  

In a letter to the Buffalo News, one medical school administrator estimated students from for-profit school have paid for “nearly 50 percent of the clerkship slots in the state.”

“At the University at Buffalo (UB), over 80 percent of students are New York State residents; they shouldn’t be displaced by international students,” said Michael Cain, MD, vice president of health sciences at UB and dean of the Jacobs School of Medicine. “We never wanted to ban students from for-profit, offshore schools; we only want to guarantee that our students get the clerkships they need.”

Cain added that the issue may become more pronounced as the number of medical schools enrollees grow. Within New York, Cain said schools have “expanded class size significantly,” while nationally, medical school enrollment hit an all-time high of 20,630 in 2015, according to the the Association of American Medical Colleges.

Administrators at offshore schools argued to the Wall Street Journal that it makes sense to pay hospitals when they’re offering important assistance to their students. The administrators only said the work their students perform benefits the state because graduates are more likely to work in underserved neighborhoods.

The offshore schools haven’t been able of buying additional slots at hospital since 2014, thanks to the New York State Education Department’s ongoing review, which the Wall Street Journal reports is expected to be completed in the next year.

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.